Literature DB >> 17653650

Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation.

Carlo Fabris1, Pierluigi Toniutto, Davide Bitetto, Rosalba Minisini, Ezio Fornasiere, Carlo Smirne, Mario Pirisi.   

Abstract

BACKGROUND: Experimental evidence and clinical studies suggest that the renin-angiotensin system and its inhibitors may play a role in regulating the mechanisms of liver fibrosis development. The present study aimed to verify whether carriage of specific angiotensin-converting enzyme (ACE) insertion (I)/deletion (D) allelic variants, modulating angiotensin II generation, could affect the outcome of recurrent hepatitis C after liver transplantation, via several metabolic pathways.
METHODS: Forty-five (29 men) recipients, with a median histological follow-up of 60 months after orthotopic liver transplantation (OLT), were studied. ACE gene I/D polymorphism was assessed by means of a polymerase chain reaction procedure. Fibrosis progression was evaluated annually during the follow-up.
RESULTS: Weight gain 1 year post-OLT (defined as an increase in body mass index, BMI, of >0.5 kg/m(2)) was significantly more common among D/ carriers (22/22 vs. 16/23, P < 0.005); patients who 1 year after OLT had an increase in their BMI value of >0.5 kg/m(2) more frequently had a triglycerides/cholesterol ratio of <or= 0.7 (16/22 vs. 8/23, chi-squared test P < 0.02). This association was stronger in men. Female D/D homozygotes had the highest probability of showing significant liver fibrosis (7/10) in comparison with men (11/29) and I/ women (1/6) (P < 0.01).
CONCLUSIONS: In patients with recurrent hepatitis C, carriers of the D allele appeared to gain more weight after liver transplantation, and in male liver recipients, the D allele was associated with a peculiar lipid profile that was associated with a slower rate of allograft fibrosis progression. Among female recipients, carriage of the D allele may favor more severe allograft fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653650     DOI: 10.1007/s00535-007-2040-1

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  34 in total

1.  Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C.

Authors:  Yuki Terui; Takafumi Saito; Hisayoshi Watanabe; Hitoshi Togashi; Sumio Kawata; Yoshihiro Kamada; Shigeru Sakuta
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

2.  Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis.

Authors:  J R Jonsson; A D Clouston; Y Ando; L I Kelemen; M J Horn; M D Adamson; D M Purdie; E E Powell
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  The angiotensin I-converting enzyme.

Authors:  E G Erdös; R A Skidgel
Journal:  Lab Invest       Date:  1987-04       Impact factor: 5.662

4.  The association between hepatitis C infection and survival after orthotopic liver transplantation.

Authors:  Lisa M Forman; James D Lewis; Jesse A Berlin; Harold I Feldman; Michael R Lucey
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

5.  Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation.

Authors:  Pierluigi Toniutto; Carlo Fabris; Claudio Avellini; Rosalba Minisini; Davide Bitetto; Elisabetta Rossi; Carlo Smirne; Mario Pirisi
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

Review 6.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

7.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Authors:  Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

8.  Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C.

Authors:  Victor I Machicao; Hugo Bonatti; Murli Krishna; Bashar A Aqel; Frank J Lukens; Justin H Nguyen; Barry G Rosser; Raj Satyanarayana; Hani P Grewal; Winston R Hewitt; Denise M Harnois; Julia E Crook; Jeffery L Steers; Rolland C Dickson
Journal:  Transplantation       Date:  2004-01-15       Impact factor: 4.939

9.  Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.

Authors:  A H Danser; M A Schalekamp; W A Bax; A M van den Brink; P R Saxena; G A Riegger; H Schunkert
Journal:  Circulation       Date:  1995-09-15       Impact factor: 29.690

10.  PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1).

Authors:  B Rigat; C Hubert; P Corvol; F Soubrier
Journal:  Nucleic Acids Res       Date:  1992-03-25       Impact factor: 16.971

View more
  1 in total

Review 1.  Theoretical basis of a beneficial role for vitamin D in viral hepatitis.

Authors:  Khanh vinh quốc Lương; Lan Thi Hoàng Nguyễn
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.